Ikena Oncology Inc expected to post a loss of 19 cents a share - Earnings Preview

ImageneBio

07/03/2025 12:35

Ikena Oncology Inc IKNA.OQ IKNA.O is expected to show a fall in quarterly revenue when it reports  results on May 12 (estimated) for the period ending December 31 2024

​LSEG's mean analyst estimate for Ikena Oncology Inc is for a loss of 19 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Ikena Oncology Inc is $3.00​, above​ its last closing price of $1.43. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.25
-0.27
-0.21
Beat
21.3
Jun. 30 2024
-0.33
-0.35
-0.28
Beat
19.4
Mar. 31 2024
-0.41
-0.41
-0.33
Beat
20​
Dec. 31 2023
-0.43
-0.47
Missed
-9.8
​​Sep. 30 2023
-0.42
-0.43
-0.40
Beat
7
Jun. 30 2023
-0.46
-0.47
-0.44
Beat
7.3​
Mar. 31 2023
-0.47
-0.47
-0.39
Beat
16.6
Dec. 31 2022
-0.53
-0.48
-0.40
Beat
16.1

This summary was machine generated March 7 at 12:35 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)